Published in Lancet on November 01, 1997
Management of brain injury after resuscitation from cardiac arrest. Neurol Clin (2008) 1.29
A randomised trial to investigate the efficacy of magnesium sulphate for refractory ventricular fibrillation. Emerg Med J (2002) 1.01
Breakthrough in cardiac arrest: reports from the 4th Paris International Conference. Ann Intensive Care (2015) 0.81
The role of magnesium in the emergency department. Emerg Med J (2002) 0.80
Antiarrhythmia drugs for cardiac arrest: a systemic review and meta-analysis. Crit Care (2013) 0.79
Magnesium in in-hospital cardiac arrest. Lancet (1998) 0.78
Current pharmacological advances in the treatment of cardiac arrest. Emerg Med Int (2011) 0.77
Part 6. Pediatric advanced life support: 2015 Korean Guidelines for Cardiopulmonary Resuscitation. Clin Exp Emerg Med (2016) 0.75
Clinical trials in cardiac arrest and subarachnoid hemorrhage: lessons from the past and ideas for the future. Stroke Res Treat (2013) 0.75
Part 3. Advanced cardiac life support: 2015 Korean Guidelines for Cardiopulmonary Resuscitation. Clin Exp Emerg Med (2016) 0.75
Magnesium in in-hospital cardiac arrest. Lancet (1998) 0.75
Acyl Ghrelin Improves Synapse Recovery in an In Vitro Model of Postanoxic Encephalopathy. Mol Neurobiol (2015) 0.75
Best evidence topic report. Intravenous magnesium in shock-resistant tachyarrhythmias. Emerg Med J (2006) 0.75
The effectiveness of right heart catheterization in the initial care of critically ill patients. SUPPORT Investigators. JAMA (1996) 17.62
Evaluating the yield of medical tests. JAMA (1982) 14.05
Effect of nesiritide in patients with acute decompensated heart failure. N Engl J Med (2011) 7.62
Regression modelling strategies for improved prognostic prediction. Stat Med (1984) 7.09
Use of medical resources and quality of life after acute myocardial infarction in Canada and the United States. N Engl J Med (1994) 6.78
A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group. N Engl J Med (1997) 6.19
Cardiac troponin T levels for risk stratification in acute myocardial ischemia. GUSTO IIA Investigators. N Engl J Med (1996) 5.94
Racial variation in the use of coronary-revascularization procedures. Are the differences real? Do they matter? N Engl J Med (1997) 5.80
Value of the history and physical in identifying patients at increased risk for coronary artery disease. Ann Intern Med (1993) 5.59
Outcome of acute myocardial infarction according to the specialty of the admitting physician. N Engl J Med (1996) 5.51
A brief self-administered questionnaire to determine functional capacity (the Duke Activity Status Index). Am J Cardiol (1989) 5.50
Relationship of depression to increased risk of mortality and rehospitalization in patients with congestive heart failure. Arch Intern Med (2001) 4.85
Kinetics of Borrelia burgdorferi dissemination and evolution of disease after intradermal inoculation of mice. Am J Pathol (1991) 4.59
Sex, clinical presentation, and outcome in patients with acute coronary syndromes. Global Use of Strategies to Open Occluded Coronary Arteries in Acute Coronary Syndromes IIb Investigators. N Engl J Med (1999) 4.53
Regional variation across the United States in the management of acute myocardial infarction. GUSTO-1 Investigators. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries. N Engl J Med (1995) 4.29
Effect of amlodipine on morbidity and mortality in severe chronic heart failure. Prospective Randomized Amlodipine Survival Evaluation Study Group. N Engl J Med (1996) 4.25
Cost effectiveness of early discharge after uncomplicated acute myocardial infarction. N Engl J Med (2000) 4.19
1999 update: ACC/AHA guidelines for the management of patients with acute myocardial infarction. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction). J Am Coll Cardiol (1999) 4.15
Cost effectiveness of thrombolytic therapy with tissue plasminogen activator as compared with streptokinase for acute myocardial infarction. N Engl J Med (1995) 3.69
Prognostic value of a treadmill exercise score in outpatients with suspected coronary artery disease. N Engl J Med (1991) 3.63
Predictors of outcome in patients with acute coronary syndromes without persistent ST-segment elevation. Results from an international trial of 9461 patients. The PURSUIT Investigators. Circulation (2000) 3.61
Referral patterns for coronary artery disease treatment: gender bias or good clinical judgment? Ann Intern Med (1992) 3.39
Predictors of 30-day mortality in the era of reperfusion for acute myocardial infarction. Results from an international trial of 41,021 patients. GUSTO-I Investigators. Circulation (1995) 3.38
Scorecard cardiovascular medicine. Its impact and future directions. Ann Intern Med (1994) 3.32
Job strain and the prevalence and outcome of coronary artery disease. Circulation (1995) 3.22
Cancer in the offspring of radiation workers: a record linkage study. BMJ (1997) 3.13
Resuscitation preferences among patients with severe congestive heart failure: results from the SUPPORT project. Study to Understand Prognoses and Preferences for Outcomes and Risks of Treatments. Circulation (1998) 3.11
The SUPPORT prognostic model. Objective estimates of survival for seriously ill hospitalized adults. Study to understand prognoses and preferences for outcomes and risks of treatments. Ann Intern Med (1995) 3.08
Prognostic importance of social and economic resources among medically treated patients with angiographically documented coronary artery disease. JAMA (1992) 3.06
A randomized trial of immediate versus delayed elective angioplasty after intravenous tissue plasminogen activator in acute myocardial infarction. N Engl J Med (1987) 3.04
Clinical data bases. Accomplishments and unrealized potential. Med Care (1985) 2.83
Determinants of the use of coronary angiography and revascularization after thrombolysis for acute myocardial infarction. N Engl J Med (1996) 2.83
ACC/AHA guidelines for the management of patients with acute myocardial infarction. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction). J Am Coll Cardiol (1996) 2.81
Difference in countries' use of resources and clinical outcome for patients with cardiogenic shock after myocardial infarction: results from the GUSTO trial. Lancet (1997) 2.80
Comparison of predictions based on observational data with the results of randomized controlled clinical trials of coronary artery bypass surgery. J Am Coll Cardiol (1988) 2.59
Matrix metalloproteinase expression and production by alveolar macrophages in emphysema. Am J Respir Crit Care Med (1997) 2.55
Link between the angiographic substudy and mortality outcomes in a large randomized trial of myocardial reperfusion. Importance of early and complete infarct artery reperfusion. GUSTO-I Investigators. Circulation (1995) 2.53
Patient-specific predictions of outcomes in myocardial infarction for real-time emergency use: a thrombolytic predictive instrument. Ann Intern Med (1997) 2.52
Factors affecting sensitivity and specificity of exercise electrocardiography. Multivariable analysis. Am J Med (1984) 2.49
Reduction in heart failure events by the addition of a clinical pharmacist to the heart failure management team: results of the Pharmacist in Heart Failure Assessment Recommendation and Monitoring (PHARM) Study. Arch Intern Med (1999) 2.44
Cardiogenic shock complicating acute coronary syndromes. Lancet (2000) 2.42
Effects of mental stress on myocardial ischemia during daily life. JAMA (1997) 2.30
Comparison of cefuroxime with or without intranasal fluticasone for the treatment of rhinosinusitis. The CAFFS Trial: a randomized controlled trial. JAMA (2001) 2.29
Cardiac troponin T and cardiac troponin I: relative values in short-term risk stratification of patients with acute coronary syndromes. GUSTO-IIa Investigators. Clin Chem (1998) 2.27
A comparison of U.S. and Canadian cardiac catheterization practices in detecting severe coronary artery disease after myocardial infarction: efficiency, yield and long-term implications. J Am Coll Cardiol (1999) 2.24
Effect of lipid-lowering therapy on early mortality after acute coronary syndromes: an observational study. Lancet (2001) 2.23
Adenosine as an adjunct to thrombolytic therapy for acute myocardial infarction: results of a multicenter, randomized, placebo-controlled trial: the Acute Myocardial Infarction STudy of ADenosine (AMISTAD) trial. J Am Coll Cardiol (1999) 2.23
Mental stress--induced myocardial ischemia and cardiac events. JAMA (1996) 2.20
Elevated levels of matrix metalloproteinases in bronchoalveolar lavage fluid of emphysematous patients. Thorax (1997) 2.19
A randomized controlled trial of epoprostenol therapy for severe congestive heart failure: The Flolan International Randomized Survival Trial (FIRST). Am Heart J (1997) 2.16
Value of serial troponin T measures for early and late risk stratification in patients with acute coronary syndromes. The GUSTO-IIa Investigators. Circulation (1998) 2.09
Prognostic value of the admission electrocardiogram in acute coronary syndromes. JAMA (1999) 2.08
Plasma D-dimer as a marker for postoperative deep venous thrombosis. A study after total hip or knee arthroplasty. Thromb Haemost (1994) 2.08
Influence of diabetes mellitus on clinical outcome in the thrombolytic era of acute myocardial infarction. GUSTO-I Investigators. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries. J Am Coll Cardiol (1997) 2.08
Angiographic findings and outcome in diabetic patients treated with thrombolytic therapy for acute myocardial infarction: the GUSTO-I experience. J Am Coll Cardiol (1996) 2.07
Cardiac rupture, mortality and the timing of thrombolytic therapy: a meta-analysis. J Am Coll Cardiol (1990) 2.06
Patients with acute coronary syndromes without persistent ST elevation undergoing percutaneous coronary intervention benefit most from early intervention with protection by a glycoprotein IIb/IIIa receptor blocker. Eur Heart J (2002) 2.06
The last word on GUSTO, for now. Ann Intern Med (1994) 2.02
Exercise treadmill score for predicting prognosis in coronary artery disease. Ann Intern Med (1987) 1.98
Continuing evolution of therapy for coronary artery disease. Initial results from the era of coronary angioplasty. Circulation (1994) 1.91
Time from symptom onset to treatment and outcomes after thrombolytic therapy. GUSTO-1 Investigators. J Am Coll Cardiol (1996) 1.91
Relationship between antecedent angina pectoris and short-term prognosis after thrombolytic therapy for acute myocardial infarction. Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) Study Group. Am Heart J (1990) 1.90
Absence of sex bias in the referral of patients for cardiac catheterization. N Engl J Med (1994) 1.90
Age and outcome with contemporary thrombolytic therapy. Results from the GUSTO-I trial. Global Utilization of Streptokinase and TPA for Occluded coronary arteries trial. Circulation (1996) 1.87
Bedside multimarker testing for risk stratification in chest pain units: The chest pain evaluation by creatine kinase-MB, myoglobin, and troponin I (CHECKMATE) study. Circulation (2001) 1.86
Total sputum nitrate plus nitrite is raised during acute pulmonary infection in cystic fibrosis. Am J Respir Crit Care Med (1998) 1.84
Platelet glycoprotein IIb/IIIa inhibitors reduce mortality in diabetic patients with non-ST-segment-elevation acute coronary syndromes. Circulation (2001) 1.83
Atrial fibrillation in the setting of acute myocardial infarction: the GUSTO-I experience. Global Utilization of Streptokinase and TPA for Occluded Coronary Arteries. J Am Coll Cardiol (1997) 1.80
Contemporary management of patients with left ventricular systolic dysfunction. Results from the Study of Patients Intolerant of Converting Enzyme Inhibitors (SPICE) Registry. Eur Heart J (1999) 1.76
Consequences of reocclusion after successful reperfusion therapy in acute myocardial infarction. TAMI Study Group. Circulation (1990) 1.74
Influence of diabetes mellitus on clinical outcomes across the spectrum of acute coronary syndromes. Findings from the GUSTO-IIb study. GUSTO IIb Investigators. Eur Heart J (2000) 1.73
Phosphorylation of subunit proteins of intermediate filaments from chicken muscle and nonmuscle cells. Proc Natl Acad Sci U S A (1979) 1.72
Prognostic value of a coronary artery jeopardy score. J Am Coll Cardiol (1985) 1.71
Outcome of patients with diabetes mellitus and acute myocardial infarction treated with thrombolytic agents. The Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) Study Group. J Am Coll Cardiol (1993) 1.70
Estimating the likelihood of significant coronary artery disease. Am J Med (1983) 1.69
Advanced coronary artery disease: Appropriate end points for trials of novel therapies. Am Heart J (2001) 1.67
Sustained ventricular arrhythmias in patients receiving thrombolytic therapy: incidence and outcomes. The GUSTO Investigators. Circulation (1998) 1.66
Long-term survival benefits of coronary artery bypass grafting and percutaneous transluminal angioplasty in patients with coronary artery disease. J Thorac Cardiovasc Surg (1996) 1.64
Facilitation of early percutaneous coronary intervention after reteplase with or without abciximab in acute myocardial infarction: results from the SPEED (GUSTO-4 Pilot) Trial. J Am Coll Cardiol (2000) 1.63
Geographic variability in outcomes within an international trial of glycoprotein IIb/IIIa inhibition in patients with acute coronary syndromes. Results from PURSUIT. Eur Heart J (2000) 1.62
Clinical determinants of mortality in patients with angiographically diagnosed ischemic or nonischemic cardiomyopathy. J Am Coll Cardiol (1997) 1.62
Prognostic value of radionuclide angiography in medically treated patients with coronary artery disease. A comparison with clinical and catheterization variables. Circulation (1990) 1.61
Depression and long-term mortality risk in patients with coronary artery disease. Am J Cardiol (1996) 1.61
Genetic variants of microsomal epoxide hydrolase and glutamate-cysteine ligase in COPD. Eur Respir J (2008) 1.59
Creatine kinase-MB elevation after percutaneous coronary intervention predicts adverse outcomes in patients with acute coronary syndromes. Eur Heart J (2004) 1.59